Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
0(0%)
Results Posted
14%(1 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_1
6
60%
Ph phase_2
4
40%

Phase Distribution

6

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
6(60.0%)
Phase 2Efficacy & side effects
4(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

70.0%

7 of 10 finished

Non-Completion Rate

30.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(7)
Terminated(3)

Detailed Status

Completed7
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
77.8%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (60.0%)
Phase 24 (40.0%)

Trials by Status

withdrawn110%
completed770%
terminated220%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00

NCT01903018
completedphase_2

A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer

NCT00824343
completedphase_2

Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression

NCT00835419
completedphase_1

Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer

NCT00899054
completedphase_1

Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma

NCT00882063
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT01903018Phase 2

A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00

Completed
NCT00824343Phase 2

A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer

Completed
NCT00835419Phase 2

Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression

Completed
NCT00899054Phase 1

Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer

Completed
NCT00882063Phase 1

Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma

Completed
NCT00843050Phase 2

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

Terminated
NCT00898287Phase 1

Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer

Completed
NCT00547404Phase 1

Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma

Withdrawn
NCT00407498Phase 1

Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms

Completed
NCT00408018Phase 1

Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms

Terminated

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10